Pancreatic Cancer Research

ResearcherUniversity of California, San FranciscoActive in the last 2 years

Akihisa Fukuda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-1940-596X; OpenAlex author ID A5016827188, A5060776135. Sources: OpenAlex.

Their work

Papers
23 (first author 10, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
55
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper · 2023: 2 papers · 2024: 3 papers · 2025: 4 papers · 2026: 3 papers

Papers 23

  1. Corrigendum to Polybromo 1/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer. First author DOI 10.1172/jci206371↗
  2. Comparison of Comprehensive Serum miRNA Sequencing and Apolipoprotein A2 Isoforms for Early Detection of Pancreatic Cancer. Co-author DOI 10.3390/cancers18071177↗
  3. Epigenetic Control of Spatiotemporal Dynamics of Pancreatic Cancer Cells via Brg1–Rac1 Signaling First author DOI 10.64898/2026.05.04.722641↗
  4. Neoadjuvant chemoradiotherapy using moderately hypofractionated intensity-modulated radiotherapy for borderline resectable pancreatic cancer : Outcomes and pro… Co-author DOI 10.1007/s00066-025-02433-9↗
  5. Proposing oligo-recurrence criteria in pancreatic ductal adenocarcinoma: A stratified analysis of locoregional treatment benefits. Co-author DOI 10.1016/j.pan.2025.04.012↗
  6. Polybromo 1/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer. First author DOI 10.1172/jci177533↗
  7. Neoadjuvant Chemoradiotherapy Using Moderately Hypofractionated Intensity-Modulated Radiotherapy Versus Upfront Surgery for Resectable Pancreatic Cancer: A Ret… Co-author DOI 10.1245/s10434-025-16956-z↗
  8. Identification of Ppy-lineage cells as a novel origin of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/path.6295↗
  9. Reduction of butyrate-producing bacteria in the gut microbiome of Japanese patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.09.002↗
  10. Early detection of pancreatic cancer by comprehensive serum miRNA sequencing with automated machine learning. First author DOI 10.1038/s41416-024-02794-5↗
  11. Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity-modulated radiotherapy for resectable pancreatic cancer: A pros… Co-author DOI 10.1002/cam4.6470↗
  12. Brg1 controls stemness and metastasis of pancreatic cancer through regulating hypoxia pathway. Co-author DOI 10.1038/s41388-023-02716-4↗
  13. Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase… Co-author DOI 10.1186/s12885-022-09244-6↗
  14. The role of the SWI/SNF chromatin remodeling complex in pancreatic ductal adenocarcinoma. First author DOI 10.1111/cas.14768↗
  15. SNAIL2 contributes to tumorigenicity and chemotherapy resistance in pancreatic cancer by regulating IGFBP2. Co-author DOI 10.1111/cas.15162↗
  16. Visualization of stem cell activity in pancreatic cancer expansion by direct lineage tracing with live imaging. First author DOI 10.7554/elife.55117↗
  17. Promoter-Level Transcriptome Identifies Stemness Associated With Relatively High Proliferation in Pancreatic Cancer Cells. Co-author DOI 10.3389/fonc.2020.00316↗
  18. Paraplegia as an initial manifestation of pancreatic cancer. First author DOI 10.1002/jgh3.12194↗
  19. Nardilysin inhibits pancreatitis and suppresses pancreatic ductal adenocarcinoma initiation in mice. First author DOI 10.1136/gutjnl-2017-315425↗
  20. ARID1A Maintains Differentiation of Pancreatic Ductal Cells and Inhibits Development of Pancreatic Ductal Adenocarcinoma in Mice. First author DOI 10.1053/j.gastro.2018.03.039↗
  21. Molecular mechanism of intraductal papillary mucinous neoplasm and intraductal papillary mucinous neoplasm-derived pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jhbp.246↗
  22. The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma. First author DOI 10.1038/ncb2916↗
  23. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Co-author DOI 10.1016/j.ccr.2011.03.002↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiroshi Seno · 14 shared papers, 2018–2026 · strength 2.21
  2. Etsuro Hatano · 10 shared papers, 2022–2026 · strength 1.80
  3. Toshihiko Masui · 9 shared papers, 2021–2026 · strength 1.52
  4. Kazuyuki Nagai · 7 shared papers, 2022–2026 · strength 1.27
  5. Takahisa Maruno · 8 shared papers, 2018–2026 · strength 1.08
  6. Makoto Sono · 6 shared papers, 2019–2026 · strength 0.97
  7. Motoyuki Tsuda · 7 shared papers, 2018–2026 · strength 0.95
  8. Munenori Kawai · 5 shared papers, 2021–2026 · strength 0.91
  9. Michio Yoshimura · 5 shared papers, 2022–2025 · strength 0.89
  10. Kei Iimori · 4 shared papers, 2024–2026 · strength 0.77
  11. Osamu Araki · 5 shared papers, 2018–2026 · strength 0.76
  12. Shinji Üemoto · 6 shared papers, 2018–2023 · strength 0.65
  13. Dieter Saur · 4 shared papers, 2021–2026 · strength 0.64
  14. Satoshi Ogawa · 5 shared papers, 2018–2026 · strength 0.63
  15. Kei Yamane · 3 shared papers, 2025 · strength 0.62
  16. Takahiro Iwai · 3 shared papers, 2025 · strength 0.62
  17. Shujiro Yazumi · 3 shared papers, 2019–2026 · strength 0.48
  18. Masashi Kanai · 3 shared papers, 2022–2025 · strength 0.48
  19. Takashi Mizowaki · 3 shared papers, 2022–2025 · strength 0.48
  20. Junichi Matsubara · 2 shared papers, 2025 · strength 0.41
  21. Kozo Ikuta · 4 shared papers, 2018–2024 · strength 0.38
  22. Kyoichi Takaori · 4 shared papers, 2018–2022 · strength 0.36
  23. Akihisa Yamamoto · 1 shared paper, 2026 · strength 0.36
  24. Motomu Tanaka · 1 shared paper, 2026 · strength 0.36
  25. Kosuke Minaga · 2 shared papers, 2024–2026 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.